The percentage of identified somatic changes is comparable to previous reports 11, 12, 13, 14, 15, whereas the BRCA1/2 germline mutation frequency is higher than the expected frequency in a constitutive ovarian cancer cases (~19% vs. 11–15.3%) 3, 4, 5, 6, 7. The gene discussed is BRCA1; the disease is ovarian cancer.